{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.1","upperLimit":"18.3","value":"7.5"},{"groupId":"OG001","lowerLimit":"0.1","upperLimit":"36.4","value":"9.1"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"52.7","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) on treatment based on RECIST 1.1 criteria. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly.","id":"OG000","title":"[Dose Level II] Pembrolizumab + Trebananib (Colorectal)"},{"description":"Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly.","id":"OG001","title":"[Dose Level II] Pembrolizumab + Trebananib (Ovarian)"},{"description":"Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly.","id":"OG002","title":"[Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma)"}],"paramType":"NUMBER","populationDescription":"The analysis population will include patients enrolled in the dose escalation and dose expansion portions of the trial. Per protocol, the dose escalation and dose expansion data may be combined for patients with the same cancer type who received the same treatment doses.","reportingStatus":"POSTED","timeFrame":"Median follow-up was 29.3 months (range 0.9 - 42.0 months).","title":"Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}